Aktiviteettini
						
							
							
							
							
								lokakuuta 23, 2019
							
						
					
				- 
			4.48admin nam kirjoitti uuden viestin keskusteluryhmään: latest journey.
 - 
			4.45
 - 
			4.42
 - 
			4.40
 
						
							
							
							
							
								heinäkuuta 11, 2019
							
						
					
				- 
			16.56Marshall Collins kirjoitti uuden viestin keskusteluryhmään: 7.11 Feedback.
 
						
							
							
							
							
								heinäkuuta 9, 2019
							
						
					
				- 
			15.22
 
Keskustelualueet
Kickoff Feedback
				
				
					Marshall Collins, muokattu 6 Vuodet sitten.
				
				
				
				
					
					
						
							Youngling
						
					
					
						
							
							
								Viestejä: 10
							
						
					
					
						
							Liittymispäivä: 28.3.18
						
					
					
						
							
							
							
						
						
							
	
		
			
				
					
						
	
		
	
	
	
		
			Viimeisimmät viestit
		
	
					
				
				
		
	
						
					
				
				
				
					
						
							
								
	
	
		
	
	
		
		
			
				
				
			
		
		
		
	
	
							
						
						
							
	
		
			
		
		
	
	
						
					
				
			
			
			- additional data to support claims (early diagnosis would be beneficial, what are these?) 
- are there studies to confirm this?
- Current presentation is a little too abstract, but for the value prop you'll want to provide data with progression of patient diagnosed early/late
- at what point does therapy start? 5 months is too early for behavior
- value props should be measurable, so setting up problem with data in value prop allow you to have a hard number to measure
- no data showing how tech of eye-tracking is effective. Even in a short pitch, it's good to have that data visible
- short pitch, however long slides with text to read. Should focus on what you're saying.
- how early can this be detected through any means? Average age of diagnosis, but what is current flow? Is this based on an assumption and then wait 3 years?
- what's customer acquisition cost? This would affect overall self-assessment
- business protection is going to be unique access to data sets, and relationships with key organizations. This is more broad than any IP
- don't know cost, reimbursement, it's screening not diagnostic. This is for pitching to angel investors, and currently the estimates are inflated
- value prop is very strong, HIC assessment is well done to recognize it's early
- start to think about giving "us" (wildcard) permission to believe that this technology, or functionality will be enough to move forward
- don't need to see the evidence, just identify what you can show
- subjective diagnostis to objective diagnosis is easy to understand
- using off the shelf technology is good and bad- may need to flesh out more about what works, why it works etc
- what are the numbers to support why this would be compelling?
- compelling need is clear, however there's no compelling story yet- show what people are doing today and the flow through pediatrician, where does your solution fit in?
- how often would this be used? Once by every clinician, multiple, mixed? Need to show one image to represent
- evidence standpoint: can it be used as monitoring of therapy? Unclear that this has longitudinal value which affects revenue models
- how long for this? once for 30 seconds, or over months?
		- are there studies to confirm this?
- Current presentation is a little too abstract, but for the value prop you'll want to provide data with progression of patient diagnosed early/late
- at what point does therapy start? 5 months is too early for behavior
- value props should be measurable, so setting up problem with data in value prop allow you to have a hard number to measure
- no data showing how tech of eye-tracking is effective. Even in a short pitch, it's good to have that data visible
- short pitch, however long slides with text to read. Should focus on what you're saying.
- how early can this be detected through any means? Average age of diagnosis, but what is current flow? Is this based on an assumption and then wait 3 years?
- what's customer acquisition cost? This would affect overall self-assessment
- business protection is going to be unique access to data sets, and relationships with key organizations. This is more broad than any IP
- don't know cost, reimbursement, it's screening not diagnostic. This is for pitching to angel investors, and currently the estimates are inflated
- value prop is very strong, HIC assessment is well done to recognize it's early
- start to think about giving "us" (wildcard) permission to believe that this technology, or functionality will be enough to move forward
- don't need to see the evidence, just identify what you can show
- subjective diagnostis to objective diagnosis is easy to understand
- using off the shelf technology is good and bad- may need to flesh out more about what works, why it works etc
- what are the numbers to support why this would be compelling?
- compelling need is clear, however there's no compelling story yet- show what people are doing today and the flow through pediatrician, where does your solution fit in?
- how often would this be used? Once by every clinician, multiple, mixed? Need to show one image to represent
- evidence standpoint: can it be used as monitoring of therapy? Unclear that this has longitudinal value which affects revenue models
- how long for this? once for 30 seconds, or over months?